eif-3.D Antibody

What is eIF-3D and what cellular functions does it perform?

eIF-3D is a subunit of the eukaryotic initiation factor 3 (eIF3) complex, an approximately 800-kilodalton protein assembly crucial for translation initiation. Recent research has revealed that eIF-3D possesses an unexpected and specialized function: it serves as an mRNA cap-binding protein providing an alternative pathway for cap-dependent translation initiation beyond the canonical eIF4E mechanism .

The protein has been crystallized at 1.4 Å resolution, revealing structural homology to endonucleases involved in RNA turnover . eIF-3D makes specific contacts with the mRNA cap structure, and these interactions are essential for assembling translation initiation complexes on specific mRNAs, including cell proliferation regulators like c-Jun . Notably, eIF-3D specifically targets and regulates translation of a subset of mRNAs involved in cell proliferation, differentiation, and apoptosis, employing different modes of RNA stem-loop binding to mediate either translational activation or repression .

What are recommended protocols for eIF-3D antibody validation?

Validating the specificity of eIF-3D antibodies requires multiple complementary approaches:

• Western blot validation: Confirm detection of a protein band at the expected molecular weight of approximately 63-66 kDa. Additional validation should include:

  • Positive controls using recombinant eIF-3D protein

  • Negative controls using samples where eIF-3D has been depleted via siRNA knockdown

  • Testing in multiple cell lines with varying eIF-3D expression levels

• Immunoprecipitation (IP) validation:

  • Perform IP using the eIF-3D antibody followed by Western blotting with a different eIF-3D antibody

  • Confirm co-immunoprecipitation of known interacting partners such as other eIF3 subunits (eIF3A, eIF3B) and potentially eIF4F complex components (eIF4G, eIF4A)

• siRNA depletion: A robust validation approach involves knocking down eIF-3D using siRNA and demonstrating diminished signal in immunoblotting or immunofluorescence, as demonstrated in several studies .

• Mass spectrometry confirmation: For definitive validation, immunoprecipitated samples can be analyzed by MALDI-TOF mass spectrometry to confirm the peptide fingerprint corresponds to eIF-3D, as shown in autoantigen identification studies .

What sample preparation methods are optimal for eIF-3D immunoblotting?

Optimal sample preparation for eIF-3D immunoblotting involves several critical steps:

• Cell lysis buffer composition: Use a buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, 0.5% Nonidet P-40 alternative, 0.5 mM DTT, and protease inhibitor cocktail . This composition preserves eIF-3D integrity while effectively solubilizing membrane-associated translation complexes.

• Mechanical disruption: After initial detergent lysis, pass the lysate through an 18G needle four times to ensure complete disruption of cellular compartments and release of eIF-3D from translation complexes .

• Centrifugation parameters: Clarify lysates by centrifugation at 13,000g for 10 minutes at 4°C .

• Protein denaturation: Heat samples in LDS sample buffer at 70°C for 5 minutes rather than boiling at higher temperatures, which may cause aggregation of large protein complexes .

• Gel selection: Utilize 4-12% Bis-Tris gradient gels for optimal resolution of eIF-3D (approximately 63-66 kDa) and potential post-translationally modified variants .

These conditions have been validated in multiple studies examining eIF-3D interactions and have consistently provided reliable results.

How can eIF-3D antibodies be used in immunofluorescence studies?

When employing eIF-3D antibodies for immunofluorescence studies, researchers should consider:

• Expected cellular localization: eIF-3D primarily displays a fine cytoplasmic speckled pattern, consistent with its role in cytoplasmic translation complexes .

• Fixation method: For optimal preservation of eIF-3D epitopes, use 4% paraformaldehyde fixation for 10-15 minutes at room temperature, followed by gentle permeabilization with 0.2% Triton X-100 to maintain cytoplasmic architecture.

• Antibody dilution optimization: Conduct a dilution series to determine the optimal concentration that maximizes specific signal while minimizing background. Typically, a 1:100 to 1:500 dilution range is appropriate for most commercial eIF-3D antibodies in immunofluorescence applications.

• Co-staining validation: Consider co-staining with antibodies against other eIF3 subunits or translation factors to confirm the specificity of the observed pattern. Colocalization with these markers provides additional validation of antibody specificity.

• Control experiments: Include cells treated with eIF-3D siRNA to demonstrate reduced signal intensity, confirming specificity of the antibody staining pattern.

How can eIF-3D antibodies be optimized for studying cap-binding functionality?

Investigating eIF-3D's cap-binding function requires specialized approaches:

• Cap analog competition assays: Design experiments incorporating m7GTP cap analogs that compete with endogenous capped mRNAs for eIF-3D binding. This approach helps distinguish between cap-dependent and cap-independent functions of eIF-3D .

• Mutational analysis: When studying eIF-3D cap-binding, consider comparing wild-type eIF-3D with mutants affecting the cap-binding surface. Specific mutations in the cap-binding domain have been shown to dramatically reduce incorporation of c-Jun mRNA into translation complexes while leaving other mRNAs like ACTB unaffected .

• Domain-specific antibodies: For advanced studies, consider using or developing antibodies specifically targeting the cap-binding domain of eIF-3D, which can be particularly useful in determining whether this domain is accessible in different cellular contexts or protein complexes.

• Cap-binding domain deletion: Experiments using eIF-3D constructs lacking the cap-binding domain (like eIF3d1 helix11) can serve as valuable controls, as these constructs may act as dominant-negative when eIF-3D cap-binding function is required .

• Cross-linking and immunoprecipitation: To identify direct RNA targets of eIF-3D's cap-binding activity, optimize UV cross-linking protocols before immunoprecipitation with eIF-3D antibodies, followed by RNA sequencing of bound transcripts.

What experimental approaches can reveal eIF-3D's interactions with eIF4F complex components?

Studying the dynamic interactions between eIF-3D and the eIF4F complex requires sophisticated methodological approaches:

• Protein-protein crosslinking: Treat cells with protein-protein crosslinkers such as dithiobis[succinimidylpropionate] (DSP) at 1 mM for 30 minutes prior to cell lysis to capture transient interactions between eIF-3D and eIF4F components .

• Co-immunoprecipitation optimization:

  • Use antibodies against eIF-3D to pull down associated proteins and probe for eIF4F complex components (eIF4G, eIF4A, eIF4E)

  • Validate findings through reciprocal co-IPs using antibodies against eIF4F components

  • Include RNase treatment controls to distinguish RNA-dependent versus direct protein-protein interactions

• Phosphorylation-dependent interactions: Research indicates that eIF-3D's interaction with eIF4F components is regulated by phosphorylation. Treatment with CK2 inhibitors like CX-5011 significantly decreases eIF-3D's ability to co-precipitate eIF4A and eIF4G1 (by 37% and 24%, respectively), while not affecting eIF-3D's association with eIF3b . This suggests that:

  • Phosphorylation status should be monitored using phospho-specific antibodies

  • Phosphatase inhibitors should be included in lysis buffers

  • Phosphomimetic (DD) and phospho-dead (NN) mutants can serve as valuable controls

• Structural analysis considerations: When designing interaction studies, consider that eIF-3D is positioned at the interface between the eIF3 and eIF4F complexes according to structural models and biochemical data .

How can researchers investigate eIF-3D's role in specialized translation during cellular stress?

To study eIF-3D's function during cellular stress:

• Stress condition optimization: Subject cells to various stress conditions (e.g., oxidative stress, ER stress, nutrient deprivation) that are known to inhibit canonical eIF4E-dependent translation. Monitor eIF-3D-dependent translation during these conditions using reporter constructs.

• Polysome profiling: Use polysome profiling to assess the impact of eIF-3D knockdown on translation during normal and stress conditions. Studies show that eIF-3D depletion causes a pronounced defect in translation initiation, characterized by an increase in 80S monosome peaks and decreased polysome content .

• Reporter systems: Design reporter constructs containing 5' UTRs of known eIF-3D-dependent mRNAs (such as c-Jun) fused to luciferase. Compare translation efficiency of these reporters versus control reporters in wild-type and eIF-3D-depleted cells under various stress conditions .

• Transcript-specific translation analysis: Perform quantitative RT-PCR on RNA isolated from polysome fractions to determine how eIF-3D depletion affects translation of specific mRNAs during stress .

• RNA immunoprecipitation: Use eIF-3D antibodies for RNA immunoprecipitation (RIP) experiments followed by sequencing to identify the subset of mRNAs that remain associated with eIF-3D during stress conditions, potentially revealing stress-specific translation regulation mechanisms.

What methodological considerations are important when studying eIF-3D as an autoantigen?

Research has identified eIF-3D as a novel autoantigen in a small percentage (0.44%) of polymyositis patients . When investigating eIF-3D as an autoantigen:

• Patient sera screening methods:

  • Radio-labeled protein immunoprecipitation (IPP) has proven effective for detecting anti-eIF-3D autoantibodies in patient samples

  • Indirect immunofluorescence to detect the characteristic fine cytoplasmic speckled pattern associated with anti-eIF-3D antibodies

  • IPP-Western blotting using commercial anti-eIF-3D antibodies to confirm the identity of immunoprecipitated proteins

• Immunoprecipitation technique: For identification of eIF-3D as an autoantigen, non-radiolabeled immunoprecipitation has shown the presence of 37, 38, 40, 42, 66, 95, and 110 kDa bands corresponding to different eIF3 complex subunits (eIF3G, eIF3I, eIF3H, eIF3E/F, eIF3L/D, eIF3B and eIF3A respectively) .

• Mass spectrometry analysis: MALDI-TOF MS and Swiss-Prot analysis of peptide fingerprints provide definitive identification of eIF-3D and other eIF3 subunits in immunoprecipitated samples .

• Control samples: Include appropriate disease-specific and healthy control sera in all experiments to establish specificity of the autoantibody response .

• Clinical correlation analysis: Document comprehensive clinical information from autoantibody-positive patients to identify potential associations between anti-eIF-3D antibodies and specific disease features, treatment responses, or prognosis .

How can researchers effectively study alterations in eIF-3D expression and its impact on disease progression?

To investigate eIF-3D's role in disease progression, particularly in cancer contexts:

What are the most effective strategies for studying eIF-3D phosphorylation and its functional consequences?

Research has shown that phosphorylation regulates eIF-3D function, particularly its interaction with the eIF4F complex. To study this:

• Phosphorylation site analysis:

  • Use phospho-specific antibodies targeting known phosphorylation sites on eIF-3D

  • Employ phosphoproteomic approaches to identify novel phosphorylation sites

  • Conduct site-directed mutagenesis to generate phosphomimetic (e.g., Ser/Thr to Asp) and phospho-dead (e.g., Ser/Thr to Asn) mutants of eIF-3D

• Kinase identification and inhibition:

  • Studies have identified Casein Kinase II (CkII/CK2) as a regulator of eIF-3D phosphorylation

  • Use selective inhibitors like CX-5011 to block CK2 activity and assess effects on eIF-3D function

  • Consider testing other kinases that may regulate eIF-3D in different contexts

• Functional rescue experiments:

  • In contexts where CkII is knocked down or inhibited, test whether expressing wild-type, phospho-mimetic, or phospho-dead eIF-3D can rescue observed phenotypes

  • Research shows that phospho-mimetic eIF-3D (DD) can significantly rescue defects caused by CkII knockdown, while phospho-dead eIF-3D (NN) cannot

• Interaction studies:

  • Assess how phosphorylation status affects eIF-3D's interactions with eIF4F components

  • CK2 inhibition reduces eIF-3D's interaction with eIF4A and eIF4G1 without affecting its association with eIF3b, suggesting phosphorylation specifically regulates eIF3-eIF4F interactions

• Translational impact assessment:

  • Determine how phosphorylation of eIF-3D affects its ability to participate in translation initiation

  • Measure translation of specific mRNAs known to be eIF-3D-dependent under different phosphorylation conditions

What experimental design is recommended for studying eIF-3D's interactions with 3'-UTRs of mRNAs?

Recent research has revealed that eIF3 can engage with 3'-UTR termini of highly translated mRNAs , adding complexity to our understanding of eIF-3D function:

• Crosslinking and immunoprecipitation protocols:

  • For capturing transient RNA-protein interactions, use UV crosslinking before immunoprecipitation with eIF-3D antibodies

  • Consider using formaldehyde or other reversible crosslinkers to preserve protein-protein interactions within larger complexes

  • For detecting potential interactions with polyA-binding proteins, treat cells with protein-protein crosslinkers like DSP (1 mM) for 30 minutes before lysis

• RNA-binding domain mapping:

  • Design truncation mutants of eIF-3D to identify regions responsible for 3'-UTR interactions

  • Compare these with domains involved in 5' cap recognition to understand potential coordinated regulation

• Reporter constructs:

  • Create reporter systems with various 3'-UTR sequences fused to a standard coding region

  • Assess how manipulation of eIF-3D levels affects translation efficiency dependent on different 3'-UTR elements

• Competitive binding assays:

  • Test whether 5' cap binding and 3'-UTR interactions are cooperative or competitive

  • Design experiments to determine if these interactions are sequential or simultaneous in the translation process

• Polysome association analysis:

  • Compare polysome association of mRNAs with different 3'-UTR characteristics following eIF-3D manipulation

  • Assess whether eIF-3D-3'-UTR interactions correlate with translation efficiency or mRNA stability

How can researchers address inconsistent results with eIF-3D antibodies in different experimental contexts?

Inconsistent results with eIF-3D antibodies may stem from several factors:

• Epitope accessibility issues:

  • eIF-3D exists in large complexes where certain epitopes may be masked

  • Test multiple antibodies targeting different regions of eIF-3D

  • For fixed samples, optimize antigen retrieval methods to improve epitope exposure

• Post-translational modification interference:

  • Phosphorylation and other modifications can affect antibody recognition

  • Consider using phosphatase treatment of samples if phosphorylation is suspected to interfere with antibody binding

  • Compare results using antibodies known to be sensitive or insensitive to phosphorylation status

• Protein complex integrity:

  • Harsh lysis conditions may disrupt eIF-3D-containing complexes

  • Use gentler lysis buffers (with lower detergent concentrations) when studying intact complexes

  • Consider stabilizing protein-protein interactions with reversible crosslinkers before lysis

• Cell type and context specificity:

  • eIF-3D function and regulation varies across cell types and conditions

  • Validate antibody performance in each specific experimental system

  • Document cell type-specific differences in eIF-3D expression, localization, or complex formation

• Antibody batch variability:

  • Different lots of the same antibody may show performance variations

  • Validate each new lot against previous successful experiments

  • Consider pooling antibody lots for long-term studies requiring consistent reagents

What are the critical considerations when designing siRNA knockdown experiments targeting eIF-3D?

When designing siRNA knockdown experiments for eIF-3D:

• siRNA design strategy:

  • Target regions of eIF-3D mRNA with minimal homology to other eIF3 subunits

  • Design multiple siRNAs targeting different regions to confirm phenotypes are not due to off-target effects

  • Include controls for non-targeting siRNAs and mock transfection

• Knockdown validation:

  • Verify knockdown efficiency at both mRNA level (by qRT-PCR) and protein level (by Western blotting)

  • Monitor levels of other eIF3 subunits, as knockdown of certain subunits (like eIF3e) can affect levels of other subunits including eIF3d

• Functional assessment:

  • Perform polysome profiling to assess the impact on global translation

  • Research shows eIF-3D knockdown causes pronounced defects in translation initiation, marked by increased 80S monosome peaks and decreased polysome content

• Timing considerations:

  • Translation factors typically have long half-lives; allow sufficient time (often 48-72 hours) for effective depletion

  • For acute effects, consider using inducible knockdown systems or CRISPR interference approaches

• Rescue experiments:

  • Design rescue constructs containing silent mutations in the siRNA target sequence

  • Test whether wild-type eIF-3D or specific mutants (e.g., cap-binding mutants, phosphorylation site mutants) can rescue knockdown phenotypes

How should researchers interpret changes in eIF-3D levels in relation to specific disease contexts?

Interpreting alterations in eIF-3D levels requires comprehensive analysis:

When analyzing eIF-3D expression changes:

• Establish normal baseline: Compare expression to appropriate normal tissue controls, considering tissue-specific expression patterns.

• Distinguish direct vs. indirect effects: Determine whether eIF-3D alterations are driving pathology or are secondary consequences of disease processes.

• Evaluate mechanism specificity: Assess whether effects depend on:

  • Cap-binding function

  • Phosphorylation status

  • Interactions with specific protein partners (e.g., GRP78 in cervical carcinoma)

  • Regulation of specific target mRNAs

• Consider compensatory mechanisms: Evaluate alterations in other translation initiation factors that might compensate for or synergize with eIF-3D changes.

• Integrate with broader pathways: Place eIF-3D alterations in context of relevant signaling pathways and cellular processes specific to the disease under study.

What analytical frameworks help distinguish eIF-3D-specific effects from general translation impairment?

Distinguishing eIF-3D-specific effects from general translation defects requires careful experimental design and analysis:

• Transcriptome-wide approaches:

  • RNA-seq of polysome fractions following eIF-3D manipulation to identify specifically affected mRNAs

  • Ribosome profiling to assess changes in translation efficiency at the genome-wide level

  • Compare results with manipulation of other translation factors to identify eIF-3D-specific patterns

• Target mRNA analysis:

  • Research shows eIF-3D specializes in translating mRNAs with complex 5' UTRs, particularly those involved in signaling and stress response

  • Focused analysis of these transcript classes can reveal eIF-3D-specific regulation

  • The c-Jun mRNA is a well-established eIF-3D-dependent transcript that can serve as a positive control

• Mutational approach:

  • Compare effects of wild-type eIF-3D with function-specific mutants:

    • Cap-binding domain mutants (affect specific subset of mRNAs)

    • Phosphorylation site mutants (affect eIF4F interactions)

    • Truncation mutants lacking specific domains

• Temporal analysis:

  • Acute vs. chronic depletion may reveal different sets of eIF-3D-dependent processes

  • Time-course experiments can distinguish primary from secondary effects

• Structural data integration:

  • Interpret functional findings in context of structural information about eIF-3D's position in translation complexes

  • Consider how mutations or modifications affect structural interactions within the larger initiation complex